| Page 2 | Kisaco Research
 
Animal Health, Nutrition and Technology Innovation Europe 2022
21-23 Feb 2022
London, UK
Now in its 7th year, Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier Innovation Summit showcasing the most exciting investment opportunities globally and connecting businesses with investors and strategic corporate partners. Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.Following overwhelming feedback from the market, we have significantly expanded our programme this year with new focused content on nutrition and technology, alongside our production and companion animal health content. We will be running 4 separate innovation showcases in production animal health, companion animal health, nutrition, and technology.Our new programme will address the full extent of this ever-evolving market. We are excited to provide an innovation platform that is bigger than ever and to continue to play a critical role in shaping the future of the animal health industry by presenting the most exciting innovations in prediction, prevention, and cure.Book now to come and see for yourself!
Visit Site
 

Justin Victor

Litigation Shareholder
Greenberg Traurig

Justin K. Victor is a seasoned first-chair trial lawyer focusing on trade secrets litigation, corporate governance disputes, and other high-stakes commercial litigation and arbitration. Known for his experience and trusted counsel, Mr. Victor is frequently sought after to represent clients in critical, "bet-the-company" cases. With the ability to navigate complex legal challenges, Mr.

Read full bio

Justin Victor

Litigation Shareholder
Greenberg Traurig

Justin Victor

Litigation Shareholder
Greenberg Traurig

Justin K. Victor is a seasoned first-chair trial lawyer focusing on trade secrets litigation, corporate governance disputes, and other high-stakes commercial litigation and arbitration. Known for his experience and trusted counsel, Mr. Victor is frequently sought after to represent clients in critical, "bet-the-company" cases. With the ability to navigate complex legal challenges, Mr. Victor has obtained temporary restraining orders, preliminary injunctions, and permanent injunctions in both state and federal courts to protect clients against trade secret misappropriation and enforce restrictive covenants.

2025 Sample Attendee List
RCM Accessing Success
HPRI Harmonizing Tech & Talent
 

Eric Zudak

CEO
Thalocan Research Innovations

Eric has been working with clinical research teams since 2005, primarily focused on process engineering and technology for the education of Investigators and CRAs. During his time with Trifecta Clinical, Eric led the commercial implementation of enterprise solutions as the Account Director to a fortune 500 Pharma Sponsor. Eric also led client assessment and education programs for many of Trifecta’s portfolio customers, and implementation programs for a large device company as well as several small Biotech’s and CROs.

Read full bio

Eric Zudak

CEO
Thalocan Research Innovations

Eric Zudak

CEO
Thalocan Research Innovations

Eric has been working with clinical research teams since 2005, primarily focused on process engineering and technology for the education of Investigators and CRAs. During his time with Trifecta Clinical, Eric led the commercial implementation of enterprise solutions as the Account Director to a fortune 500 Pharma Sponsor. Eric also led client assessment and education programs for many of Trifecta’s portfolio customers, and implementation programs for a large device company as well as several small Biotech’s and CROs. In 2012 Eric led the OUS expansion, opening Trifecta’s first EU based sponsor account and later the first Asia PAC account in Japan.

Eric was asked to serve as co-chair of the WCG Diversity, Equity and Inclusion Council, which he did proudly for 18 months until his departure. Eric counts the opportunity to learn from the DE&I community among the most significant of his career.

Since 2016, his work has been focused on projects related to endpoint assessments for clinical studies in the immuno-dermatology therapeutic area. Working with Sponsors, CROs and Medical Societies, Eric has supported a variety of endpoint measurement and validation projects. These projects include scale and instruction for Atopic Dermatitis, Generalized Pustular Psoriasis, Hand and Foot Syndrome, Hand Eczema, as well as adapting existing scales for used in assessing severity in skin of color.

Eric hopes to improve the disease severity tools, processes, and data in the study of inflammatory skin disease for all stakeholders. The goal is to drive improved metrics for Sponsors, reduce the burden on trial investigators, and maximize the contribution of clinical trial volunteers.

Eric is a graduate of The University of Evansville school of Fine Arts.